medigraphic.com
Colegio de Medicina Interna de México.

2014, Número 6

<< Anterior Siguiente >>

Med Int Mex 2014; 30 (6)


Metas de control de la presión arterial en pacientes con enfermedad renal crónica sin tratamiento dialítico

Ruiz-Mejía R, Ortega-Olivares LM, Suárez-Otero R

Idioma: Español
Referencias bibliográficas: 55
Paginas: 675-686
Archivo PDF: 486.33 Kb.


RESUMEN

La hipertensión arterial es un problema con alta prevalencia mundial, su asociación con la insuficiencia renal, como causa o consecuencia, incrementa la morbilidad y la mortalidad secundarias a ésta; se han publicado guías de tratamiento del paciente hipertenso, pero aún hay controversia respecto del paciente con enfermedad renal crónica sin tratamiento dialítico. Este artículo revisa la evidencia disponible acerca de los mecanismos posibles de acción de la hipertensión arterial en la insuficiencia renal y sus consecuencias; también propone el tratamiento y las metas control de las cifras de presión arterial.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. The Seven Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. JAMA 2003;289:2560-2571.

  2. Barquera S, Campos-Nonato I, Hernández-Barrera L, et al. Hypertension in Mexican adults: results from the National Health and Nutrition Survey 2006. Salud Pública Méx 2010;52:63-71.

  3. Global Health Risks: Mortality and burden of disease attributable to selected Major Risks. Geneva: World Health Organization 2009. http://www.who.int/healthinfo/global_ burden_disease/GlobalHealthRisks_report_full_pdf. (revisado el 20 Julio 2014).

  4. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomized trials. Lancet 2003;362:1527-1535.

  5. Whelton PK, He J, et al. Primary prevention of hypertension: clinical and public health advisory from the national high blood pressure education program. JAMA 2002;228:1882- 1888.

  6. Amato D, Alvarez C, Limones M, et al. Prevalence of chronic kidney disease in a urban Mexican population. Kid Int 2005;68:11-17.

  7. Paniagua R, Ramos A, Fabian R, et al. Peritoneal dialysis in Latin America, chronic kidney disease and dialysis in Mexico. Perit Dial Int 2007;27:405-409.

  8. American Diabetes Association. Standards of medical care in diabetes 2014. Diabetes Care 2014;37:14-80.

  9. Mortiz KM, Singh RR, Probyn ME, et al. Developmental programming of a reduced nephron endowment: more than just a baby's birth weight. A J Phys 2009;296:1-5.

  10. Rostand SG, Drueke TB. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 1999;56:383-392.

  11. Guyton AC, Coleman TG, Young DB, et al. Salt balance and long-term blood pressure control. Annu Rev Med 1980; 31:15-27.

  12. Lifton RP. Genetic dissection of human blood pressure variation: common pathways from rare phenotypes. Harvey Lect 2004-2005;100:71-101.

  13. Leenen FH. The central role of the brain aldosteroneouabain pathway in salt-sensitive hypertension. Biochim Biophys Acta 2010;1802:1132-1139.

  14. Van Huysse JW, Amin MS, Yang B, et al. Salt induced hypertension in a mouse model of Liddle syndromes mediated by epithelial sodium channels in the brain. Hypertension 2012;60:691-698.

  15. Kohan DE. Endotelins in the normal and disease kidney. Am J Kidney Dis 1997;29:2-26.

  16. Gavras H, Ribeiro AB, Kohlmann O, et al. Effects of a specific inhibitor of the vascular action of vasopressin in humans. Hypertension 1984;6:1-156.

  17. Vaziri ND. Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens 2004;13:93-99.

  18. Feig DI, Kang D, Johnson R. Uric acid and cardiovascular risk. N Engl J Med 2008;358:1811-1821.

  19. Fleischmann G, Fillafer G, Matterer H, et al. Prevalence of chronic kidney disease in patients with suspected sleep apnoea. Nephrol Dial Transplant 2010;25:181-186.

  20. Harrap SB, Davies DL, Macnicol AM, et al. Renal, cardiovascular and hormonal characteristics of young adult with autosomal dominant polycystic kidney disease. Kidney Int 1991;40:501-508.

  21. Desir GV. Renalase deficiency in chronic kidney disease, and its contribution to hypertension and cardiovascular disease. Curr Opin Nephrol Hypertens 2008;17:181-185.

  22. Wiig H, Schröder A, Neuhofer W, et al. Immune cells control skin lymphatic electrolyte homeostasis and blood pressure. J Clin Invest 2013;123:2803-2815.

  23. Rao A, Nistala R. Is there a role for the incretin system in blood pressure regulation? Curr Hypertens Rep 2014;16- 417.

  24. Nguyen H, Chiasson V, Chatterjee P, et al. Interleukin 17 causes rho-kinasa mediated endothelial dysfunction and hypertension. Cardiovasc Res 2013;97:696-704.

  25. Herrera J, Ferrebus A, Macgregor EG, et al. Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis. J Am Sec Nephrol 2006;17:218.

  26. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000;356:147-152.

  27. Parikh Nisha I, Hwang Shih-Jen, Larson Martin G, et al. Cardiovascular disease risk factors in chronic kidney disease overall burden and rates of treatment and control. Arch Intern Med 2006;166:1884-1891.

  28. Mancia G, Fagard R, Narkiewikz K, et al. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) ESH/ESC Guidelines for the management of arterial hypertension. Eur Heart J 2013;34 :2159-2221.

  29. Cohen DL, Huan Y, Townsend RR. Home blood pressure monitoring in CKD. Am J Kidney Dis 2014. Article in Press.

  30. National Clinical Guideline Centre (UK) Hypertension: The clinical management of primary hypertension in adults: Update of Clinical Guidelines 18 and 34. (NICE Clinical Guidelines, No. 127). London: Royal College of Physicians 2011.http://www.ncbi.nlm.nih.gov/books/NBK83274/ (revisado el 20 de julio 2014).

  31. Nasothimiou EG, Karpettas N, Dafni MG, et al. Patient’s preference for ambulatory versus home blood pressure monitoring. J Human Hypert 2014;28:224-229.

  32. Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105- 1187.

  33. National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43:1-290.

  34. James PA, Oparil SL, Carter B, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults. Report from the panel members appointed to the eighth joint national committee (JNC 8). Special Communication JAMA 2013:284-427.

  35. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study. Ann Intern Med 1995;123:754.

  36. Wright Jr JT, Bakris G, Greene T, et al. African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288:2421-2431.

  37. Schrier RW, Estacio RO, Esler A, et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy, and stroke. Kidney Int 2002;61:1086.

  38. Toto RD, Mitchel HC, Smith RD, et al. “Strict” blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int 1995;48:851-859.

  39. Fogo A, Breyer JA, Smith MC, et al. Accuracy of the diagnosis of hypertensive nephrosclesosis in African Americans: A report from the African American Study of Kidney Disease (ASSK) Trial. ASSK Pilot Study Investigators. Kidney Int 1997;51:244-252.

  40. Mann JF, Gerstein HC, Pegue J, et al. Renal insufficiency as a predict tor of cardiovascular outcomes and the impact of ramipril. The HOPE randomized trial. Ann Intern Med 2001;134:629-636.

  41. Weiner DE, Tighiouart H, Levey AS, et al. Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease. J Am Soc Nephrol 2007;18:960-966.

  42. Kunz R, Friedrich C, Wolbers M, et al. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Ann Intern Med 2008;148:30-48.

  43. Toto DR. Treatment of hypertension in Chronic Kidney Disease. Semin Nephrol 2005;25:435-439.

  44. Gouva C, Nikolopoulos P, Ioannidis JP, et al. Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial. Kidney Int 2004;66:753-760.

  45. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) Diet. DASHSodium Collaborative Research Group. N Engl J Med 2001;344:3-10.

  46. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003;289:2534-2544.

  47. Thomas G, Shishehbor M, Brill D, et al. New hypertension guidelines: One size fits most? Clev Clin J Med 2014;81:178- 188.

  48. Parving HH, Hovind P. Microalbuminuria in type 1 and type 2 diabetes mellitus: evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy. Curr Hypertens Rep 2002;4:387-393.

  49. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004;351:1952- 1961.

  50. Jacobsen P, Andersen S, Rossing K, et al. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003;63:1874-1880.

  51. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004;292:2227-2236.

  52. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857-1863.

  53. Jafar TH, Stark PC, Schmid CH, et al, AIPRD Study Group. Angiotensin-converting enzyme inhibition and progression of renal disease: proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001;60:1131-1140.

  54. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensinconverting- enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 2003;361:117-124.

  55. Navaneethan SD, Nigwekar SU, Sehgal AR, et al. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009;4:542-551.




2020     |     www.medigraphic.com